Arbutus Biopharma Corp., of Vancouver, British Columbia, said it signed a share purchase agreement with Roivant Sciences Inc., of New York, for the sale of convertible preferred shares for gross proceeds of $116.4 million, which the company intends to use to further develop and advance its clinical and preclinical hepatitis B virus (HBV) pipeline programs.